
Celcuity’s Multi-Target PAM Inhibitor Shows Unprecedented Survival Benefit in PIK3CA Wild-Type Advanced Breast Cancer
Key Takeaways Historic Progression-Free Survival Benefit in HR+/HER2- Breast Cancer: Gedatolisib reduced the risk of progression or death by 76% (triplet) and 67% (doublet), marking unprecedented results in a Phase III setting for this population. …